RecruitingPhase I/IIFemale onlyEN originalOvarian cancer

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony diagnostycznie rak jajnika, rak otrzewnej lub rak jajowodu, który szybko rośnie
  • Widoczne nowotwory widoczne na badaniach obrazowych
  • Rak powrócił po 1-3 liniach poprzedniego leczenia
  • Biopsia potwierdzająca typ nowotworu
  • Dobry ogólny stan zdrowia (zdolność do pełnienia normalnych czynności)
  • Jeśli pacjent ma HIV, musi być ono kontrolowane lekami
  • Jeśli pacjent ma zapalenie wątroby, wirus musi być niewykrywalny lub kontrolowany

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 17, 2026
Sex
Female only

Therapies / drugs in trial

Locations (28)

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

New Haven, United States

The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

Louisville, United States

Dana-Farber Cancer Institute ( Site 0015)

Boston, United States

Memorial Sloan Kettering Cancer Center ( Site 0003)

New York, United States

OU Health University of Oklahoma Medical Center ( Site 7000)

Oklahoma City, United States

Texas Oncology - DFW ( Site 8000)

Fort Worth, United States

Houston Methodist Hospital ( Site 0010)

Houston, United States

START Mountain Region ( Site 0008)

West Valley City, United States

University of Virginia Health System ( Site 0011)

Charlottesville, United States

McGill University Health Centre ( Site 0100)

Montreal, Canada

Rambam Health Care Campus ( Site 0202)

Haifa, Israel

Shaare Zedek Medical Center ( Site 0201)

Jerusalem, Israel

Rabin Medical Center ( Site 0203)

Petah Tikva, Israel

Sheba Medical Center ( Site 0200)

Ramat Gan, Israel

Institut Català d'Oncologia - L'Hospitalet ( Site 0302)

L'Hospitalet de Llobregat, Spain

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)

Majadhonda, Spain

Clinica Universidad de Navarra ( Site 0301)

Madrid, Spain

Hospital General Universitario de Valencia ( Site 0305)

Valencia, Spain

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)

Barcelona, Spain

Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)

Madrid, Spain

Hospital Universitario 12 de Octubre ( Site 0304)

Madrid, Spain

Hospital Universitario Virgen de la Victoria ( Site 0306)

Málaga, Spain

University Hospitals Sussex NHS Foundation Trust ( Site 0404)

Brighton, United Kingdom

Royal Marsden Hospital ( Site 0402)

Fulham, United Kingdom

The Royal Marsden NHS Foundation Trust. ( Site 0403)

Sutton, United Kingdom

Barts Health NHS Trust ( Site 0401)

London, United Kingdom

Guy s & St Thomas NHS Foundation Trust ( Site 0400)

London, United Kingdom

The Christie NHS Foundation Trust ( Site 0405)

Manchester, United Kingdom

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.